First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.

Hiroki IshiharaKenji OmaeYuki NemotoRyo IshiyamaHidekazu TachibanaKoichi NishimuraTakashi IkedaYuki KobariHironori FukudaKazuhiko YoshidaHiroaki ShimmuraYasunobu HashimotoJunpei IizukaTsunenori KondoToshio Takagi

Published in: International journal of clinical oncology (2024)

IO-TKI therapy exhibited superior effectiveness over IO-IO therapy in terms of PFS improvement and immediate disease progression prevention and was associated with a higher risk of treatment interruption and a lower risk of needing corticosteroids.

Keyphrases

randomized controlled trial
renal cell carcinoma
systematic review
tyrosine kinase
electronic health record
chronic myeloid leukemia
advanced non small cell lung cancer
big data
replacement therapy
combination therapy
epidermal growth factor receptor
artificial intelligence